A systematic review of radiomics in pancreatitis: applying the evidence level rating tool for promoting clinical transferability

Jingyu Zhong1†, Yangfan Hu1†, Yue Xing1, Xiang Ge1, Defang Ding1, Huan Zhang2* and Weiwu Yao1*

Abstract
Background: Multiple tools have been applied to radiomics evaluation, while evidence rating tools for this field are still lacking. This study aims to assess the quality of pancreatitis radiomics research and test the feasibility of the evidence level rating tool.

Results: Thirty studies were included after a systematic search of pancreatitis radiomics studies until February 28, 2022, via five databases. Twenty-four studies employed radiomics for diagnostic purposes. The mean ± standard deviation of the adherence rate was 38.3 ± 13.3%, 61.3 ± 11.9%, and 37.1 ± 27.2% for the Radiomics Quality Score (RQS), the Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) checklist, and the Image Biomarker Standardization Initiative (IBSI) guideline for preprocessing steps, respectively. The median (range) of RQS was 7.0 (−3.0 to 18.0). The risk of bias and application concerns were mainly related to the index test according to the modified Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool. The meta-analysis on differential diagnosis of autoimmune pancreatitis versus pancreatic cancer by CT and mass-forming pancreatitis versus pancreatic cancer by MRI showed diagnostic odds ratios (95% confidence intervals) of, respectively, 189.63 (79.65–451.48) and 135.70 (36.17–509.13), both rated as weak evidence mainly due to the insufficient sample size.

Conclusions: More research on prognosis of acute pancreatitis is encouraged. The current pancreatitis radiomics studies have insufficient quality and share common scientific disadvantages. The evidence level rating is feasible and necessary for bringing the field of radiomics from preclinical research area to clinical stage.

Keywords: Pancreatitis, Machine learning, Differential diagnosis, Quality improvement, Systematic review

Key points
• More high-quality research on prognosis of acute pancreatitis is encouraged, since it has great influence on clinical decision-making but cannot be easily predicted by radiologists' assessment.
• The overall RQS rating could detect common methodological issues across radiomics research, but the biological correlation and comparison to “gold standard” item needs further modification for non-oncological radiomics studies.
• The RQS rating, TRIPOD checklist, and IBSI for preprocessing steps can serve as tools for radiomics quality evaluation in non-oncological field, while the development of a single comprehensive tool is more favorable for future evaluation.
• An evidence level rating tool has been confirmed to be feasible for the determination of the existing gap between preclinical and clinical use of radiomics research and is necessary for the overall assessment of specific clinical problems.

Background
Acute pancreatitis is a frequent pancreatic disease that is characterized by a local and systemic inflammatory response with the varying clinical course from self-limiting mild acute pancreatitis to moderate or severe acute pancreatitis which has a substantial mortality rate [1]. A plethora of studies attempted to predict the severity of acute pancreatitis to guide clinical treatment, such as the Acute Physiology and Chronic Health Evaluation (APACHE) II [2], the bedside index for severity in acute pancreatitis (BISAP) [3], and the CT severity index (CTSI) [4]. However, complexity in evaluation may hinder their clinical application, and they are not useful for predicting recurrence or local complications [2–4]. Approximately 20% of acute pancreatitis patients endure recurrent attacks and progress to chronic pancreatitis, a fibroinflammatory syndrome of the exocrine pancreas [5]. Chronic pancreatitis may present mass-like or cyst-like appearance, mimicking mass-forming pancreatitis, autoimmune pancreatitis, pancreatic cancer, and other pancreatic tumors [6]. The differential diagnosis and determination of malignancy of these lesions are hard, but it is necessary to achieve an accurate diagnosis to avoid unnecessary surgery in inflammatory conditions.

Radiomics represents the process of extracting quantitative features to transform images into high-dimensional data for capturing deeper information to support decision-making [7–11]. Current studies have shown its potential for pancreatic precision medicine, especially in diagnosis and management of pancreatic tumors [12–14]. Although the main use of radiomics lies in oncology, the radiomics approach is suitable for non-oncological research based on its nature [15–17]. However, only 5.6% of pancreatic radiomics studies investigated the role of radiomics in acute pancreatitis [18]. Most radiomics studies on chronic, mass-forming, or autoimmune pancreatitis were aimed to differentiate these inflammatory conditions from malignancy lesions [19–22]. Implanting radiomics in acute pancreatitis could provide predictive information to identify patients with worse prognosis and therefore promote personalized medical treatment. It is also important to identify patients with a high risk of chronic pancreatitis to allow for closer follow-up and early intervention. Further, the current radiomics reviews applied multiple tools for quality assessment, while the study quality and clinical value of radiomics in pancreatitis are unknown. A high level of evidence is an essential prerequisite for translating radiomics into clinical use. To the best of our knowledge, the level of evidence supporting radiomics models for clinical practice has not been fully investigated.

Hence, our review is aimed to systematically evaluate the methodology quality, reporting transparency, and risk of bias of current radiomics studies on pancreatitis, and determine their level of evidence according to the results of meta-analyses.

Methods
Protocol and registration
The protocol of the current systematic review has been drafted and registered (Additional file 1: Note S1). This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) statement [23], and the relevant checklists are available as Additional file 2.

Literature search and study selection
A systematic search of articles on radiomics in pancreatitis was performed via PubMed, Embase, Web of Science, China National Knowledge Infrastructure, and Wanfang Data until February 28, 2022, with a search string combining “radiomics” and “pancreatitis.” There was no limitation of publish period, but only articles written in English, Chinese, Japanese, German or French were eligible. The reference lists of included articles and relevant reviews were screened to identify additional eligible articles. We included primary radiomics articles whose purposes were diagnostic, prognostic, or predictive. Two reviewers each with 4 years of experience in radiomics and systematic review searched and selected articles independently. In case of disagreements, a third reviewer with 30 years of experience in abdominal radiology and experience in radiomics research would be consulted. The detailed search strategy and eligibility criteria are available in Additional file 1: Note S2.

Data extraction and quality assessment
We modified a data extraction sheet for the current review, which includes literature information, study characteristics, radiomics considerations, and model metrics (Additional file 1: Table S1) [24]. One reviewer extracted the data independently and then the other reviewer cross-checked the results. The disagreements were resolved by a third reviewer.

The Radiomics Quality Score (RQS) [10], the Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) checklist [25], the Image Biomarker Standardization Initiative (IBSI) guideline [11], and the modified Quality
Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool [26] were employed to assess the study quality (Additional file 1: Tables S2 to S5). These tools were modified to current review topic. Briefly, the RQS with 16 items was used to assess the methodological quality of radiomics according to six key domains [27]. The TRIPOD was partially modified into a 35-item checklist for application in radiomics, excluding the Additional file 1 and funding items [28]. Due to the overlapping with the RQS and the TRIPOD, only seven items relevant to pre-processing steps were selected from the IBSI guideline [29]. The QUADAS-2 tool was tailored to the current research question through signaling questions for risk of bias and application concerns [24]. Two reviewers rated the articles independently, and the disagreements were resolved by discussion with a third reviewer. The consensus reached during data extraction and quality assessment is described in Additional file 1: Note S3.

Data synthesis and analysis

The characteristics of included studies were descriptively summarized. The RQS score and the percentage of the ideal score were described as the mean score and the percentage of mean score to ideal score for each item, respectively. The adherence rates of the RQS rating, the TRIPOD checklist and the IBSI guideline were calculated as the ratio of the number of articles with basic adherence to the number of all available articles. In case a score of at least one point for each item was obtained without minus points, it was considered to have basic adherence, as those which have been reported [27–29]. During the calculation of TRIPOD, the “if done” or “if relevant” items (5c, 11, and 14b) and validation items (10c, 10e, 12, 13, 17, and 19a) were excluded from both the denominator and numerator [28, 29]. The result of QUADAS-2 assessment was summarized as proportions of high risk, low risk and unclear.

Subgroup analysis was performed to determine whether a factor influenced on the ideal percentage of RQS, the TRIPOD adherence rate, and the IBSI adherence rate, including the journal type, first authorship, biomarker, and imaging modality. According to the data distribution, Student’s t test or Mann–Whitney’s U test was used for intergroup differences, and one-way analysis of variance or Kruskal–Wallis H test was applied for multiple comparisons. The Spearman correlation test was used for the correlation analysis between the study quality (the ideal percentage of RQS, the TRIPOD adherence rate, and the IBSI adherence rate) and characteristics (the sample size and the impact factor). The SPSS software version 26.0 was used for statistical analysis. A two-tailed p value < 0.05 was recognized as statistical significance, unless otherwise specified.

In the current review, the value of radiomics in differential diagnosis of autoimmune pancreatitis versus pancreatic cancer by CT and mass-forming pancreatitis versus pancreatic cancer by MRI were repeatedly addressed. Therefore, these two clinical questions were included in the meta-analysis. We performed meta-analysis according to imaging modalities, to present the clinically practicable estimation. One reviewer directly extracted or reconstructed the two-by-two tables based on available data, and then the other reviewer cross-checked the results. The diagnostic odds ratio (DOR) with its 95% confidence interval (CI) and the corresponding p value were calculated using random effect model. The sensitivity, specificity, positive and negative likelihood ratio and their 95% CIs were also quantitatively synthesized. The hierarchical summary receiver operating characteristic (HSROC) curve was drawn for visual evaluation of diagnostic performance and heterogeneity. The Cochran’s Q test and the Higgins I² test were conducted for heterogeneity assessment. The Deeks funnel plot was constructed for publication bias. The Deeks funnel asymmetry test, Egger’s test, and Begg’s test were performed. A two-tailed p value > 0.10 indicated a low publication bias. The trim and fill method was employed to evaluate the robustness of meta-analyses. The Stata software version 15.1 with metan, midas, and metandi packages was employed for meta-analysis.

The model type and phase of image mining studies of the studies were classified according to the TRIPOD statement (Additional file 1: Table S6) [25] and a previous review (Additional file 1: Table S7) [30]. The levels of evidence supporting clinical values were rated based on the results of meta-analyses (Additional file 1: Table S8) [31, 32]. The detailed analysis methods are described in Additional file 1: Note S4.

Results

Literature search

The search identified 587 records in total, 257 of which were excluded due to duplication. After screening the remaining 330 records, 73 full texts were retrieved and reviewed. Finally, 30 studies were included (Fig. 1) [33–62]. No additional eligible study was found through hand search of their reference lists or relevant reviews.

Study characteristics

The characteristics of the 30 included studies are summarized in Table 1. Figure 2 shows the topics of the 33 models included in the 30 studies. 69.7% (23/33) models focused on the role of radiomics in differential diagnosis of pancreatitis from pancreatic tumors, while 12.1% (4/33) models employed radiomics to distinguish chronic pancreatitis from normal pancreas tissue, functional
abdominal pain, and acute pancreatitis. The remaining 18.1% (6/33) models investigated the predictive potential of radiomics in prognosis of acute pancreatitis. The literature information, model characteristics, and radiomics information of each study are present in Additional file 1: Tables S9 to S11.

Study quality
The overall mean ± standard deviation (median, range) of the RQS rating was 7.0 ± 5.0 (7.0, 3.0 to 18.0), with an overall adherence rate of 38.3% (184/480), and an ideal percentage of RQS of 20.3% (7.3/36) (Table 2; Fig. 3). Although more than nine-tenths of the studies performed feature reduction steps and reported discrimination statistics, none of the studies conducted test–retest analysis, phantom study, cutoff analysis, or cost-effectiveness analysis. All six key domains of RQS were suboptimal, among which the model performance index domain showed the highest ideal percentage of 42.7% (2.1/5).

The overall adherence rate of the TRIPOD checklist was 61.3% (478/780), excluding “if relevant,” “if done,” and “validation” items (5c, 11, 14b, 10c, 10e, 12, 13, 17, and 19a) (Table 3; Fig. 3). None of the studies reported the blinded method during the outcome assessment (item 6b), sample size calculation (item 8), and handling of missing data (item 9). The discussion section reached the highest adherence rate of 90.0% (81/90), while the adherence rate of the validation section was only 17.3% (9/52).

The overall adherence rate of IBSI preprocessing steps was 37.1% (78/210) (Fig. 4). The software for feature extraction varied among studies, including MATLAB (7/30), Pyradiomics (6/30), IBEX (5/30), and others. Three studies did not report the software used. Among these, Pyradiomics and IBEX were with IBSI compliance. The studies used manual (23/30) and automatic (1/30) methods for segmentation. However, one study did not report the segmentation method. The robustness assessment was performed in 40.0% (12/30) of the studies, all concerning the inter- and intra-reader agreements. Other preprocessing steps were sometimes conducted.

The results of the QUADAS-2 assessment are presented in Fig. 3. The risk of bias and application concerns relating to index testing were most frequently observed mainly due to the lack of external validation. The risk of bias in patient selection was rated as high in two studies due to the case–control design. Most of the studies did not provide the timing of scanning; therefore, the corresponding risk of bias was unclear. Individual assessment per study per element is present in Additional file 1: Tables S12 to S15.
The datasets for meta-analyses are present in Additional file 1: Table S16. The pooled analysis showed that the DOR (95% CI) of radiomics for distinguishing autoimmune pancreatitis versus pancreatic cancer by CT and mass-forming pancreatitis versus pancreatic cancer by MRI were 189.63 (79.65–451.48) and 135.70 (36.17–509.13), respectively (Fig. 5 and Table 4). However, their levels of evidence were both weak mainly due to the insufficient sample size. There was significant heterogeneity among studies, but the likelihood of publication bias was low. The trim and fill analysis demonstrated that there were missing datasets, but the adjusted diagnostic performance was still of statistical significance. The results of meta-analyses regardless of imaging modalities presented dramatic statistical significance (Additional file 1: Table S17). The corresponding plots of meta-analyses are present in Additional file 1: Figures S1 to S9.

### Correlations between study characteristics and quality

Figure 6 shows the potential correlation between study characteristics and its quality. The studies before and after the publication of the RQS, the TRIPOD checklist, or the IBSI guideline did not show obvious difference. Only the ideal percentage of RQS was considered to be related to the sample size ($r = 0.456$, $p = 0.011$). The results of subgroup analysis and correlation tests are present in Additional file 1: Tables S18 and S19. No difference of the ideal percentage of RQS, the TRIPOD adherence rate, and the IBSI adherence rate among subgroups has been found (all $p > 0.05$).

### Discussion

In our review, radiomics showed promising performance of diagnostic and prognostic models for multiple purposes in pancreatitis, but their levels of evidence were weak. The overall adherence rates of the RQS rating, the TRIPOD checklist, and the IBSI preprocessing steps

| Study characteristics | Data |
|-----------------------|------|
| Sample size, mean± standard deviation, median (range) | 137.5 ± 85.0, 111 (41–389) |
| Journal type, n (%) | $N = 30$ |
|   Imaging | 16 (53) |
|   Non-imaging | 14 (47) |
| First authorship, n (%) | $N = 30$ |
|   Radiologist | 24 (80) |
|   Non-radiologist | 6 (20) |
| Biomarker, n (%) | $N = 30$ |
|   Diagnostic | 24 (80) |
|   Prognostic | 6 (20) |
| Imaging modality, n (%) | $N = 30$ |
|   CT | 13 (43) |
|   EUS | 4 (13) |
|   MRI | 9 (30) |
|   PET | 4 (13) |
| Model type, n (%) | $N = 30$ |
|   Type 1a: Developed model validated with exactly the same data | 7 (23) |
|   Type 1b: Developed model validated with resampling data | 10 (33) |
|   Type 2a: Developed model validated with randomly splitting data | 12 (40) |
|   Type 2b: Developed model validated with non-randomly splitting data | 1 (3) |
|   Type 3: Developed model validated with separate data | 0 (0) |
|   Type 4: Validation only | 0 (0) |
| Phase classification, n (%) | $N = 30$ |
|   Phase 0: < 100 patients; retrospective; internal validation | 16 (53) |
|   Phase I: < 100 patients; retrospective; external validation | 2 (7) |
|   Phase II: > 100 patients; retrospective; external validation | 12 (40) |
|   Phase III: > 100 patients; prospective; external validation | 0 (0) |
|   Phase IV: real-world | 0 (0) |
were 38.3%, 61.3%, and 37.1%, respectively. The ideal percentage of RQS was positively related to the sample size. Our results implied that the level of evidence supporting clinical application and the overall study quality were suboptimal in pancreatitis radiomics research, requiring significant improvement.

Several reviews have summarized the use of radiomics in multiple pancreatic diseases from pancreatic cystic lesions to pancreatic tumors [15–22]. A comprehensive review reported that most of the pancreatic radiomics studies investigated focal pancreatic lesions, but only four studies discussed the pancreatitis [12]. In our review, radiomics has been most frequently applied to differential diagnosis of pancreatic cancer from autoimmune pancreatitis, chronic pancreatitis, or mass-forming pancreatitis. The misdiagnosis causes pancreatic cancer patients to miss the surgical opportunity, while the patients with inflammatory condition may receive unnecessary treatment. The accurate diagnosis of these lesions is hindered by mimicking imaging features [6]. Radiomics showed comparable and even better performance than radiologists’ assessment [38, 42, 46, 52, 56, 58], but their level of evidence supporting clinical translation is still weak. Therefore, more validation for the establishment of a sound evidence basis is the main issue for diagnostic. The prognosis prediction for acute pancreatitis is another topic of clinical significance. Although the CT severity index has been established for prognosis prediction of acute pancreatitis [4], the pancreatic parenchyma injury and extra-pancreatic inflammation are not visible enough in early pancreatitis. The conventional imaging features usually lag behind disease progression, which cannot help clinical decision-making. Current studies demonstrated the usefulness of radiomics in predicting severity, recurrence, progression, and extra-pancreatic necrosis [33, 35, 40, 41, 45, 59]. However, the studies were conducted by varying imaging modalities concerning separate outcomes, which do not allow further meta-analysis to establish any evidence. Besides, as a continuous disease progress, acute pancreatitis needs comprehensive prediction for multiple clinical outcomes. Corresponding
models have not been developed yet. Thus, it is more urgent to encourage more investigation into prognosis.

The inadequate quality of radiomics studies has been addressed repeatedly [15–24, 27–29]. In accordance with previous reviews, several items were always lacking including test–retest analysis, phantom study, cut-off analysis, and cost-effectiveness analysis in RQS, the blinded method during outcome assessment, sample size calculation, and handling of missing data in TRIPOD, and details of image preprocessing in selected IBSI items. In spite of these common issues across radiomics studies, there are some non-oncology specific issues. Contrary to the oncological field, the concept of biological correlate did not clearly fit the current topic [17], since the inflammatory diseases do not always relate to genomics. In prognostic studies, comparison to “gold standard” is not suitable for non-oncological diseases without a widely accepted “gold standard,” while the tumor staging is usually employed as the “gold standard” of survival prediction. The TRIPOD items and IBSI preprocessing items were suitable for non-oncological studies, since they were not specified for oncological field. We found that the ideal percentage of RQS was positively related with the sample size. We suspected that the larger sample size might allow more sufficient validation, evaluation of calibration statics, and clinical utility assessment, which could gain a higher RQS rating.

Most of the radiomics studies were oncological, but radiomics has potential clinical application in the non-oncological field [30]. Several reviews have summarized the role of radiomics in non-oncological diseases, including mild cognitive impairment and Alzheimer's disease [15], COVID-19 and viral pneumonia [16], and cardiac diseases [17]. The study quality evaluated by RQS was the main concern of these reviews. Their ideal percentage of RQS were 9.9%, 34.1%, and 19.4%, respectively. We suspected that the COVID-19 and viral pneumonia review reached a better RQS rating since the included studies were published recently with a relatively larger sample size, which allow adequate feature reduction and external validation. Actually, none of the studies in this review lacked the feature reduction, and all the studies performed validation [16]. In contrast, a significant number of previous studies did not perform feature reduction and validation. As a result, the other non-oncological radiomics reviews showed lower RQS ratings [15, 17]. Our review is in line with these non-oncological radiomics reviews with a comparable ideal

Table 2  RQS rating of included studies

| 16 items according to 6 key domains | Range | Median (range) | Percentage of ideal score, n (%) | Adherence rate, n (%) |
|-----------------------------------|-------|---------------|---------------------------------|----------------------|
| Total 16 items                    | −8 to 36 | 7 (−3 to 18) | 7.3 (20.2) | 184 (38) |
| Domain 1: protocol quality and stability in image and segmentation | 0–5 | 2 (0–2) | 1.6 (31.3) | 47 (15) |
| Protocol quality                  | 0–2 | 1 (0–1) | 0.9 (46.7) | 28 (93) |
| Multiple segmentations            | 0–1 | 1 (0–1) | 0.6 (63.3) | 19 (63) |
| Test–retest                       | 0–1 | 0 (0–0) | 0 (0) | 0 (0) |
| Phantom study                     | 0–1 | 0 (0–0) | 0 (0) | 0 (0) |
| Domain 2: feature selection and validation | −8 to 8 | −2 (−8 to 6) | 0.9 (10.8) | 42 (70) |
| Feature reduction or adjustment of multiple testing | −3 to 3 | 3 (−3 to 3) | 2.8 (93.3) | 29 (97) |
| Validation                        | −5 to 5 | −5 (−5 to 3) | −1.9 (0) | 13 (43) |
| Domain 3: biologic/clinical validation and utility | 0–6 | 1.5 (0–6) | 2.0 (33.9) | 47 (39) |
| Non-radiomics features            | 0–1 | 0.5 (0–1) | 0.5 (50.0) | 15 (60) |
| Biologic correlations             | 0–1 | 1 (0–1) | 0.6 (60.0) | 18 (60) |
| Comparison with “gold standard”   | 0–2 | 0 (0–2) | 0.8 (40.0) | 12 (40) |
| Potential clinical utility        | 0–2 | 0 (0–2) | 0.1 (6.7) | 2 (7) |
| Domain 4: model performance index | 0–5 | 2 (1–4) | 2.1 (42.7) | 34 (38) |
| Cutoff analysis                   | 0–1 | 0 (0–0) | 0 (0) | 0 (0) |
| Discrimination statistics         | 0–2 | 2 (1–2) | 1.9 (95.0) | 30 (100) |
| Calibration statistics            | 0–2 | 0 (0–2) | 0.2 (11.7) | 4 (13) |
| Domain 5: high level of evidence  | 0–8 | 0 (0–7) | 0.2 (2.9) | 1 (2) |
| Prospective study                 | 0–7 | 0 (0–7) | 0.2 (3.3) | 1 (3) |
| Cost-effectiveness analysis       | 0–1 | 0 (0–0) | 0 (0) | 0 (0) |
| Domain 6: open science and data   | 0–4 | 0 (0–1) | 0.4 (10.8) | 13 (43) |

RQS Radiomics Quality Score
percentage of RQS of 20.3%. Nevertheless, the feasibility of the TRIPOD checklist [28] and the IBSI pre-processing steps [29] have only been assessed in the oncological field. Our study initially tested and confirmed that they were useful in non-oncological field, but further validation is needed.

An evidence level rating tool has been tested in our review [31, 32]. The evidence level rating process is feasible to show the gap between academic research and clinical application in radiomics studies. It is necessary to employ this tool, since the dramatic model performance did not naturally guarantee a strong level of evidence supporting the clinical translation. However, this tool did not mention on which dataset a predictive model should be assessed, because this tool is originally developed for reviewing epidemic studies and clinical trials [31, 32]. It is recommended to perform the assessment of radiomics models on an external validation dataset [10, 11, 25]. We consider that future studies should determine the level of evidence based on results of meta-analyses of validation datasets.

We believed that the whole radiomics research community should participate in the improvement in methodological and reporting quality for a higher level of evidence to support the translation of radiomics. They need to get involved into this process, to critically appraise the study design, conduct and analyze the model, and report the study. Indeed, the IBSI guideline used in our review is an achievement gained by an independent international collaboration which works towards standardization of the radiomics methodology and reporting [11]. There are many other guidelines developed or under development by the radiomics and artificial intelligence community with the purpose to improve study quality, including Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis based on Artificial Intelligence (TRIPOD-AI) [63], Prediction model Risk Of Bias ASsessment Tool based on Artificial Intelligence (PROBAST-AI) [63], Quality Assessment of Diagnostic Accuracy Studies centered on Artificial Intelligence (QUADAS-AI) [64], Developmental and Exploratory Clinical Investigations of DEcision support systems...
## Table 3

TRIPOD adherence of included studies

| 33 Selected Items in 20 Criteria According to 6 Sections (N = 30) | Study, n (%) |
|---------------------------------------------------------------|-------------|
| **Overall (excluding 5c, 11, 14b, 10c, 10e, 12, 13, 17, and 19a)** | 478 (61) |
| **Section 1: Title and Abstract** | 14 (23) |
| 1. Title—identify developing/validating a model, target population, and the outcome | 2 (7) |
| 2. Abstract—provide a summary of objectives, study design, setting, participants, sample size, predictors, outcome, statistical analysis, results, and conclusions | 12 (40) |
| **Section 2: Introduction** | 37 (62) |
| 3a. Background—Explain the medical context and rationale for developing/validating the model | 30 (100) |
| 3b. Objective—Specify the objectives, including whether the study describes the development/validation of the model or both | 7 (23) |
| **Section 3: Methods** | 252 (65) |
| 4a. Source of data—describe the study design or source of data (randomized trial, cohort, or registry data) | 30 (100) |
| 4b. Source of data—specify the key dates | 26 (87) |
| 5a. Participants—specify key elements of the study setting including number and location of centers | 30 (100) |
| 5b. Participants—describe eligibility criteria for participants (inclusion and exclusion criteria) | 21 (70) |
| 5c. Participants—give details of treatment received, if relevant (N = 6) | 0 (0) |
| 6a. Outcome—clearly define the outcome, including how and when assessed | 30 (100) |
| 6b. Outcome—report any actions to blind assessment of the outcome | 0 (0) |
| 7a. Predictors—clearly define all predictors, including how and when assessed | 23 (77) |
| 7b. Predictors—report any actions to blind assessment of predictors for the outcome and other predictors | 15 (50) |
| 8. Sample size—explain how the study size was arrived at | 0 (0) |
| 9. Missing data—describe how missing data were handled with details of any imputation method | 0 (0) |
| 10a. Statistical analysis methods—describe how predictors were handled | 24 (80) |
| 10b. Statistical analysis methods—specify type of model, all model-building procedures (any predictor selection), and method for internal validation | 23 (77) |
| 10d. Statistical analysis methods—specify all measures used to assess model performance and if relevant, to compare multiple models (discrimination and calibration) | 30 (100) |
| 11. Risk groups—provide details on how risk groups were created, if done (N = 0) | 0 (0) |
| **Section 4: Results** | 94 (52) |
| 13a. Participants—describe the flow of participants, including the number of participants with and without the outcome. A diagram may be helpful | 16 (53) |
| 13b. Participants—describe the characteristics of the participants, including the number of participants with missing data for predictors and outcome | 24 (80) |
| 14a. Model development—specify the number of participants and outcome events in each analysis | 25 (83) |
| 14b. Model development—report the unadjusted association between each candidate predictor and outcome, if done (N = 5) | 1 (20) |
| 15a. Model specification—present the full prediction model to allow predictions for individuals (regression coefficients, intercept) | 5 (17) |
| 15b. Model specification—explain how to use the prediction model (nomogram, calculator, etc.) | 2 (7) |
| 16. Model performance—report performance measures (with confidence intervals) for the prediction model | 22 (73) |
| **Section 5: Discussion** | 81 (90) |
| 18. Limitations—Discuss any limitations of the study | 30 (100) |
| 19b. Interpretation—Give an overall interpretation of the results | 30 (100) |
| 20. Implications—Discuss the potential clinical use of the model and implications for future research | 21 (70) |
| **Section 6: Validation for Model type 2a, 2b, 3, and 4 (N = 13)** | 9 (17) |
| 10c. Statistical analysis methods—describe how the predictions were calculated | 0 (0) |
| 10e. Statistical analysis methods—describe any model updating (recalibration), if done (N = 0) | 0 (0) |
| 12. Development versus validation—Identify any differences from the development data in setting, eligibility criteria, outcome, and predictors | 5 (38) |
| 13c. Participants (for validation)—Identify any differences from the development data with the distribution of important variables | 4 (31) |
| 17. Model updating—report the results from any model updating, if done (N = 0) | 0 (0) |
| 19a. Interpretation (for validation)—discuss the results with reference to performance in the development data and any other validation data | 0 (0) |

TRIPOD: Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis
Fig. 4 IBSI preprocessing steps performed in included studies. a Adherence rate of IBSI preprocessing steps; b segmentation method; c software for radiomics feature extraction. The other software included Omni-Kinetics, Artificial Intelligent Kit, AnalysisKit, Image J, FireVoxel, and MaZda.

Fig. 5 Forest plots of diagnostic odds ratio for differentiation diagnosis. a Autoimmune pancreatitis versus pancreatic cancer by CT, b mass-forming focal pancreatitis versus pancreatic cancer by MRI.
driven by Artificial Intelligence (DECIDE-AI) [65], Standard Protocol Items: Recommendations for Intervventional Trials—Artificial Intelligence (SPIRIIT-AI) [66], Consolidated Standards of Reporting Trials—Artificial Intelligence (CONSORT-AI) [67], Standards for Reporting of Diagnostic Accuracy Study centered on Artificial Intelligence (STARD-AI) [68], Checklist for Artificial Intelligence in Medical Imaging (CLAIM) [69], etc. Their project teams and steering committees usually consisted of a broad range of experts to provide balanced and diverse views involving various stakeholder groups.

However, the importance of the participants varies with the stage from early scientific validation to later regulatory assessment. For offline preclinical validations, reporting guidelines and risk of bias assessment tools for radiomics model studies are used, emphasizing the methodological and reporting quality [63, 64]. During this stage, the researchers, authors, reviewers, and editors of radiomics studies play an important role to improve the methodological and reporting quality, and make sure only studies with adequate innovation are being published. Next, at the stage of safety and utility, the small-scale early live clinical evaluations are used to inform regulatory decisions and are part of the clinical evidence generation process [65]. With improvements of study quality, the radiomics research community could for the first time provide more robust scientific evidence for the translation of radiomics. Before clinical application, it is necessary to test the radiomics for safety and effectiveness in large-scale, comparative, and prospective trials [66–68]. Similar to the random clinical trials which are considered as the gold standard for drug therapies, the aim of these studies should be to provide stronger evidence for translation of radiomics from research application into a clinically relevant tool. Nevertheless, given the somewhat different focuses of scientific evaluation and regulatory assessment, as well as differences between regulatory jurisdictions, the health policy makers and legal experts may have a greater say in this stage.

The quality assessment results should be seen as a quality seal of the published results more than a way of underlining the possible weaknesses of the proposed model [70]. At present, the researchers are reticent in publishing the quality assessment results for their radiomics studies, and journals do not demand particular checklists for radiomics studies. Nevertheless, in this early stage of radiomics, the authors, editors, reviewers, and readers should be able to ascertain whether a radiomic study is compliant with good practice or whether the study has justified any noncompliance.

There are several limitations in our study. First, the RQS was far from perfect. Some of TRIPOD items may be not suitable for radiomics studies. We did not exhaust the IBSI checklist, but focused on preprocessing steps. Nevertheless, the current review served as an example for the application of these tools in the non-oncological field. Second, radiomics is considered as a subset of artificial intelligence, but we did not apply Checklist for Artificial Intelligence in Medical Imaging for our review [69]. This tool allows assessments on not only artificial intelligence in medical imaging that includes classification, image reconstruction, text analysis, and workflow optimization, but also general manuscript review criteria. However, many items in this tool are too general [71], and therefore hard to apply in radiomics. The tools we used could cover almost all the CLAIM items with more specific instructions. It would be interesting to assess the feasibility of CLAIM in radiomics, but it falls out of our study scope. Third, studies included in the current review focus on very different topics. It may not be fair to run meta-analyses of heterogenous studies, and this process gives insights into clinical questions with a limited number of studies [24, 72]. Indeed, only two selected clinical questions with similar settings were included in meta-analyses.

### Table 4

| Clinical question | AIP versus PC by CT | MFP versus PC by MRI |
|-------------------|---------------------|----------------------|
| Number of studies | 6                   | 4                    |
| Number of available datasets | 5/8               | 5/6                  |
| Events/sample size | 191/421            | 101/320              |
| Pooled analysis   |                     |                      |
| DOR (95% CI)      | 189.63 (79.65–451.48) | 135.70 (36.17–509.13) |
| p value for DOR   | <0.001              | <0.001               |
| Sensitivity (95% CI) | 0.90 (0.84–0.94) | 0.90 (0.81–0.95)     |
| Specificity (95% CI) | 0.95 (0.92–0.97) | 0.94 (0.86–0.98)     |
| PLR (95% CI)      | 19.01 (10.51–34.40) | 15.00 (5.94–37.92)   |
| NLR (95% CI)      | 0.10 (0.06–0.17)    | 0.11 (0.06–0.56)     |
| AUC (95% CI)      | 0.97 (0.95–0.98)    | 0.95 (0.93–0.96)     |
| Heterogeneity     |                     |                      |
| Higgins I² test (%) | 83.26%             | 97.28%               |
| Cochran’s Q test (p value) | <0.01          | <0.01                |
| Publication bias  |                     |                      |
| Egger’s test (p value) | 0.060              | 0.050                |
| Begg’s test (p value) | 0.221              | 0.221                |
| Deeks test (p value) | 0.226              | 0.538                |
| Trim and fill method |                 |                      |
| Number of missing datasets | 2                  | 2                    |
| Adjusted DOR (95% CI) | 135.11 (64.40–283.74) | 53.89 (15.95–182.00) |
| Level of evidence | Weak                | Weak                 |

AIP: autoimmune pancreatitis, AUC: area under curve, CI: confidential interval, DOR: diagnostic odds ratio, MFP: mass-forming pancreatitis, NLR: negative likelihood ratio, n/a: not applicable, PC: pancreatic cancer, PLR: positive likelihood ratio.
for evidence level rating. The increasing number of studies would allow more robust scientific data aggregation in the future. Still, this is a timely attempt to test the feasibility of the evidence level rating tool for radiomics.

In conclusion, more high-quality studies on prognosis of acute pancreatitis are encouraged, since it has great influence on clinical decision-making but could not be easily predicted by radiologists’ assessment. Although meta-analysis of studies showed fascinating potential in differentiating pancreatitis from pancreatic cancer, the level of evidence was weak. The current methodological and reporting quality of radiomics studies on pancreatitis is insufficient. Moreover, evidence rating is needed before radiomics can be translated into clinical practice.

Abbreviations
CI: Confidence interval; DOR: Diagnostic odds ratio; HSROC: Hierarchical summary receiver operating characteristic; IBSI: Image Biomarker Standardization Initiative; QUADAS-2: Modified Quality Assessment of Diagnostic Accuracy Studies; RQS: Radiomics Quality Score; TRIPOD: Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13244-022-01279-4.

Additional file 1: Supplementary Note S1. Review Protocol. Supplementary Note S2. Search Strategy and Study Selection. Supplementary Note S3. Consensus Reached during Data extraction and Quality Assessment. Supplementary Note S4. Data Synthesis and Analysis Methods. Supplementary Table S1. Data Extraction Sheet. Supplementary Table S2. Methodological Quality according to RQS Checklist. Supplementary Table S3. Reporting Completeness according to TRIPOD Statement. Supplementary Table S4. Pre-processing Steps according to IBSI Guideline. Supplementary Table S5. Risk of Bias and Concern on Application Assessment according to QUADAS-2 Tool. Supplementary Table S6. Types of Prediction Model Studies Covered by The TRIPOD Statement. Supplementary Table S7. Trials Classifications for Image Mining Tools Development Process. Supplementary Table S8. Category of Five Levels of Supporting Evidence of Meta-analyzes. Supplementary Table S9. Study Characteristics of Included Studies. Supplementary Table S10. PICOT of Included Studies. Supplementary Table S11. Radiomics Methodological Consideration of Included Studies. Supplementary Table S12. RQS Rating per Study. Supplementary Table S13. TRIPOD Adherence per Study. Supplementary Table S14. Pre-processing Steps Performed in Each Study. Supplementary Table S15. QUADAS-2 Assessment per Study. Supplementary Table S16. Model Metrics of...
Acknowledgements

The authors would like to express their gratitude to Dr. Yong Chen for sharing his experience in pancreatitis radiomics, Dr. Zihao Liu for sharing his knowledge of clinical practice in pancreatitis, Dr. Shiqi Mao for his suggestions on data visualization, and Dr. Guangcheng Zhang for English language polishing.

Author contributions

JY.Z and YH.F performed the literature search, data extraction, and quality assessment. JY.Z performed meta-analyses, visualized data, and drafted the original version of manuscript. All authors read and approved the final manuscript.

Funding

This study has received funding by National Natural Science Foundation of China (81771789, 81771790); Yangfan Project of Science and Technology Commission of Shanghai Municipal (22YF144240); Shanghai Science and Technology Commission Science and Technology Innovation Action Clinical Innovation Field (1841195300); Medicine and Engineering Combination Project of Shanghai Jiao Tong University (YG2019ZDB09); and Research Fund of Tongren Hospital, Shanghai Jiao Tong University School of Medicine (TRKYRC-202004, TRGG202101, TRYJ2021JC06).

Availability of data and materials

All data generated or analyzed during this study are included in this published article and its Additional file 1.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Received: 6 May 2022 Accepted: 26 July 2022

Published online: 20 August 2022

References

1. Biothorn L, Voermans RP, Bouwens SA et al (2020) Acute pancreatitis. Lancet 396(10252):726–734
2. Banks PA, Bollen TL, Dervenis C et al (2013) Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensus. Gut 62(1):102–111
3. Knaus WA, Draper EA, Wagner DP, Zimmerman JE (1985) APACHE II: a severity of disease classification system. Crit Care Med 13(10):818–829
4. Wu BJ, Johannesburg RS, Sun X et al (2008) The early prediction of mortality in acute pancreatitis: a large population-based study. Gut 57(12):1698–1703
5. Beyer G, Habtezion A, Werner J, Lerch MM, Mayerle J (2020) Chronic pancreatitis. Lancet 396(10249):499–512
6. Wolske KM, Ponnatapura J, Kolokythas C, Burke LMB, Tappouni R, Lalwani N (2019) Chronic pancreatitis or pancreatic tumor? A problem-solving approach. Radiographics 39(7):1965–1982
7. Lambin P, Rios-Velazquez E, Leijenaar R et al (2012) Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer 48(4):441–446
8. Gillies RJ, Kinahan PE, Hricak H (2016) Radiomics: images are more than pictures, they are data. Radiology 278(2):563–577
9. O’Connor JP, Aboagye EO, Adams JE et al (2017) Imaging biomarker roadmap for cancer studies. Nat Rev Clin Oncol 14:169–186
10. Lambin P, Leijenaar RTH, Desai TM et al (2017) Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol 14(12):749–762
11. Zwanenburg A, Valleriès M, Abdallah MA et al (2020) The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology 295(2):328–338
12. Gu D, Hu Y, Ding H et al (2019) CT radiomics may predict the grade of pancreatic neuroendocrine tumors: a multicenter study. Eur Radiol 29(12):6880–6890
13. Rigoli F, Hoye J, Lerebours R et al (2021) CT radiomic features of superior mesenteric artery involvement in pancreatic ductal adenocarcinoma: a pilot study. Radiology 310(3):610–622
14. Mapelli P, Bezzo C, Palumbo D et al (2022) 68Ga-DOTATOC PET/CT imaging and radiomic parameters in predicting histopathological prognostic factors in patients with pancreatic neuroendocrine well-differentiated tumours. Eur J Nucl Med Mol Imaging. https://doi.org/10.1007/s00259-022-05677-0
15. Won SY, Park YW, Park M, Ahn SS, Kim J, Lee SK (2020) Quality reporting of radiomics analysis in mild cognitive impairment and Alzheimer’s disease: a roadmap for moving forward. Korean J Radiol 21(12):1345–1354
16. Kao YS, Lin KT (2021) A meta-analysis of computerized tomography-based radiomics for the diagnosis of COVID-19 and viral pneumonia. Diagnostics 11(6):991
17. Ponsiglione A, Stanzione A, Cuocolo R et al (2021) Cardiac CT and MRI radiomics: systematic review of the literature and radiomics quality score assessment. Eur Radiol. https://doi.org/10.1007/s00330-021-08375-x
18. Abunahel BM, Pontre B, Kumar H, Petrov MS (2021) Pancreas image mining: a systematic review of radiomics. Eur Radiol 31(5):3447–3467
19. Virakar M, Wong VK, Morani AC, Tamm EP, Bhosale P (2021) Update on quantitative radiomics of pancreatic tumors. Abdom Radiol (NY). https://doi.org/10.1007/s00256-021-03216-3
20. Bartoli M, Barat M, Dohan A et al (2020) CT and MRI of pancreatic neuroendocrine tumors: a multicenter study. Eur Radiol 30(12):6880–6890
21. Talati V, Carmicheal J, Dhaliwal A, Jain M, Kaur S, Batra SK (2020) Radiomics in stratification of pancreatic cystic lesions: machine learning in action. Cancer Lett 432:296–304
22. Bezzo C, Mapelli P, Presotto L et al (2021) Radiomics in pancreatic neuroendocrine tumors: methodological issues and clinical significance. J Nucl Med Mol Imaging 48(12):4002–4015
23. Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71
24. Zhong J, Hu Y, Si L et al (2021) A systematic review of radiomics in osteosarcoma: utilizing radiomics quality score as a tool promoting clinical translation. Eur Radiol. https://doi.org/10.1007/s00330-021-09837-8
25. Collins GS, Reitsma JB, Altman DG, Moons KG (2015) Transparent reporting of a multivariable prediction model for individual prognosis or diagnostic accuracy: the TRIPOD statement. Ann Intern Med 162(1):55–63
26. Whiting PF, Rutjes AW, Westwood ME et al (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155(8):S29–S36
27. Park JE, Kim HS, Kim D et al (2020) A systematic review reporting quality of radiomics research in neuro-ontology: toward clinical utility and...
quality improvement using high-dimensional imaging features. BMC Cancer 2011:29
28. Park JE, Kim D, Kim HS et al (2020) Quality of science and reporting of radiomics in oncologic studies: room for improvement according to radiomics quality score and TRIPDM statement. Eur Radiol 30(1):523–536
29. Park CJ, Park YW, Ahn SS et al (2022) Quality of radiomics research on brain metastasis: a roadmap to promote clinical translation. Korean J Radiol 23(1):77–88
30. Sollini M, Antunovic L, Chiti A, Kirienko M (2019) Towards clinical application of image mining: a systematic review on artificial intelligence and radiomics. Eur J Nucl Med Mol Imaging 46(12):2656–2672
31. Ding Y, Hou Y (2021) The prognostic value of late gadolinium enhancement in heart diseases: an umbrella review of meta-analyses of observational studies. Eur Radiol 31(7):4528–4537
32. Kallia I, Markozannes G, Gunter MJ et al (2017) Obesity and gynaecological and obstetric conditions: umbrella review of the literature. BMJ jh511
33. Chen Y, Chen TW, Wu CQ et al (2019) Radiomics model of contrast-enhanced computed tomography for predicting the recurrence of acute pancreatitis. Eur Radiol 29(8):4408–4417
34. Cheng MF, Guo YL, Yen RF et al (2018) Clinical Utility of FDG PET/CT in patients with autoimmune pancreatitis: a case-control study. Sci Rep 8(1):3631
35. Cui W, Zhang W, Zhou L, Jin X, Xiao D (2021) Predictive value of CT texture analysis for recurrence in children with acute pancreatitis. Chin J Dig Surg 20(4):459–465. https://doi.org/10.3760/cma.j.cn115610-20210331-00156 (in Chinese)
36. Das A, Nguyen CC, Li F, Li B (2008) Digital image analysis of EUS images accurately differentiates pancreatic cancer from chronic pancreatitis and normal tissue. Gastrointest Endosc 67(6):861–867
37. Deng Y, Ming B, Zhou T et al (2021) Radiomics Model Based on MR images to discriminate pancreatic ductal adenocarcinoma and mass-forming chronic pancreatitis lesions. Front Oncol 11:620981
38. E L, Xu Y, Wu Z, et al (2020) Differentiation of focal-type autoimmune pancreatitis from pancreatic ductal adenocarcinoma using radiomics based on multiphasic computed tomography. J Comput Assist Tomogr 44(4):511–518
39. Frækær JB, Listskaya MV, Jørgensen AS et al (2020) Pancreatic magnetic resonance imaging texture analysis in chronic pancreatitis: a feasibility and validation study. Abdom Radiol (NY) 45(5):1497–1506
40. Hu Y, Huang X, Liu N, Tang L (2021) The value of T2WI sequence-based radiomics in predicting recurrence of acute pancreatitis. Chin J Mag Reson Imaging 12(10):12–15. https://doi.org/10.1201/issn.1674-8034.2021.10.003 (in Chinese)
41. Iramnaboob AK, Kiersan AS, Huang C, Ream JM, Rosenkantz AB (2017) Preliminary investigation of whole-pancreas 3D histogram ADC metrics for predicting progression of acute pancreatitis. Clin Imaging 42:172–177
42. Li J, Liu F, Fang X et al (2021) CT radiomics features in differentiation of focal-type autoimmune pancreatitis from pancreatic ductal adenocarcinoma: a propensity score analysis. Acad Radiol 29(5):358–366
43. Li SS, Wu ZF, Lin N (2021) CT signs combined with texture features in the differential diagnosis between focal autoimmune pancreatitis and pancreatic cancer. J Chin Clin Med Imaging 32(5):347–350. https://doi.org/10.12117/jcci.2021.05.010 (in Chinese)
44. Lin Y, Shen Y, Zhou S, Li Z, Hu D, Feng C (2019) The value of CT texture analysis in differentiating autoimmune pancreatitis from pancreatic ductal adenocarcinoma. J Pract Radiol 35(1):1174–1178. https://doi.org/10.3969/j.jpr.2019.11.015 (in Chinese)
45. Lin Q, Ji YF, Chen Y et al (2020) Radiomics model of contrast-enhanced MRI for early prediction of acute pancreatitis severity. J Magn Reson Imaging 51(2):397–406
46. Liu Z, Li M, Zuo C et al (2021) Radiomics model of dual-time 2 1/2(FDG) PET/CT imaging to distinguish between pancreatic ductal adenocarcinoma and autoimmune pancreatitis. Eur Radiol 31(9):6983–6991
47. Liu J, Hu L, Zhou B, Wu C, Cheng Y (2022) Development and validation of a novel model incorporating MR-based radiomics signature with clinical biomarkers for distinguishing pancreatic carcinoma from mass-forming chronic pancreatitis. Transl Oncol 15:10357
48. Ma X, Wang YR, Zhuo LY et al (2022) Retrospective Analysis of the Value of Enhanced CT radiomics analysis in the differential diagnosis between pancreatic cancer and chronic pancreatitis. Int J Gen Med 15:233–241
49. Mashayekhi R, Parekh VS, Faghhi M, Singh VK, Jacobs MA, Zaheer A (2020) Radiomic features of the pancreas on CT imaging accurately differentiate functional abdominal pain, recurrent acute pancreatitis, and chronic pancreatitis. Eur J Radiol 123:108787
50. Park S, Chu LC, Hruban RH et al (2020) Differentiating autoimmune pancreatitis from pancreatic ductal adenocarcinoma with CT radiomics features. Diagn Interv Imaging 101(9):555–564
51. Peng L, Zha Y, Zeng F, Liu B, Yan Y (2020) The value-based T2 histogram analysis for differential diagnosis in solid pancreatic lesions. Chin J Mag Reson Imaging 11(3):201–206. https://doi.org/10.1201/issn.1674-8034.2020.03.008 (in Chinese)
52. Ren S, Zhang J, Chen J et al (2019) Evaluation of texture analysis for the differential diagnosis of mass-forming pancreatitis from pancreatic ductal adenocarcinoma on contrast-enhanced CT images. Front Oncol 9:11171
53. Ren S, Zhao R, Zhang J et al (2020) Diagnostic accuracy of unenhanced CT texture analysis to differentiate mass-forming pancreatitis from pancreatic ductal adenocarcinoma. Abdom Radio (NY) 45(5):1524–1533
54. Ren H, Mori N, Hamada S et al (2021) Effective apparent diffusion coefficient parameters for differentiation between mass-forming autoimmune pancreatitis and pancreatic ductal adenocarcinoma. Abdom Radio (NY) 46(4):1640–1647
55. Zhang MW, Yang J, Jin ZD, Yu JG, Cai ZY, Li ZS (2010) Differential diagnosis of pancreatic cancer from normal tissue with digital imaging processing and pattern recognition based on a support vector machine of EUS images. Gastrointest Endosc 72(5):978–985
56. Zhang Y, Cheng C, Liu Z et al (2019) Radiomics analysis for the differentiation of autoimmune pancreatitis and pancreatic ductal adenocarcinoma in “T-F” FDG PET/CT. Med Phys 46(10):4520–4530
57. Zhang Y, Cheng C, Liu Z et al (2019) Differentiation of autoimmune pancreatitis and pancreatic ductal adenocarcinoma based on multi-modality texture features in 18F-FDG PET/CT. J Biomedical Eng 36(5):755–762. https://doi.org/10.7507/1001-5515.201807012 (in Chinese)
58. Zhang J, Li Q, Wang J et al (2019) Contrast-enhanced CT and texture analysis of mass-forming pancreatitis and cancer in the pancreatic head. Natl Med J China 99(33):2575–2580. https://doi.org/10.3760/cma.j.issn.0376-2491.2019.33.004 (in Chinese)
59. Zhou T, Xie CL, Shen Y et al (2021) Magnetic resonance imaging-based radiomics models to predict early extrapancreatic necrosis in acute pancreatitis. Pancreas 50(10):1368–1375
60. Zhu M, Xu C, Yu J et al (2013) Differentiation of pancreatic cancer and chronic pancreatitis using computer-aided diagnosis of endoscopic ultrasound (EUS) images: a diagnostic test. PLoS One 8(5):e63820
61. Zhu J, Wang L, Chu Y et al (2015) A new descriptor for computer-aided diagnosis of EUS images to distinguish autoimmune pancreatitis from chronic pancreatitis. Gastrointest Endosc 82(5):831–836
62. Ziegelmayer S, Kaissis G, Harder F et al (2020) Deep convolutional neural network-assisted feature extraction for diagnostic discrimination and feature visualization in pancreatic ductal adenocarcinoma (PDAC) versus autoimmune pancreatitis (AIP). J Clin Med 9(12):4013
63. Collins GS, Dhiman P, Andaur Navarro CL et al (2021) Protocol for development of a reporting guideline (TRIPDM-AI) and risk of bias tool (PROBAST-AI) for diagnostic and prognostic prediction model studies based on artificial intelligence. BMJ Open 11(7):e048008
64. Sounderajah V, Ashrafian H, Rose S et al (2021) A quality assessment tool for artificial intelligence-centered diagnostic test accuracy studies: QUADAS-AI. Nat Med 27(10):1663–1665
65. Vasely B, Nagendran M, Campbell B, DECIDE-AI expert group, et al (2022) Reporting guideline for the early-stage clinical evaluation of decision support systems driven by artificial intelligence: DECIDE-AI. Nat Med 28(5):924–933
66. Cruz Rivera S, Liu X, Chan AW, et al (2020) Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI extension. Med J Natl Med 26(9):1351–1363
67. Liu X, Cruz Rivera S, Moher D, Calvert MJ, Denniston AK, SPIRIT-AI and CONSORT-AI Working Group (2020) Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension. Nat Med 26(9):1364–1374
68. Sounderajah V, Ashrafian H, Appagantula et al (2020) Developing specific reporting guidelines for diagnostic accuracy studies assessing AI interventions: the STARD-AI Steering Group. Nat Med 26(6):807–808
69. Mongan J, Moy L, Kahn CE Jr (2020) Checklist for Artificial Intelligence in Medical Imaging (CLAIM): a guide for authors and reviewers. Radiol Artif Intell 2(2):e200029

70. Guiot J, Vaidyanathan A, Deprez L et al (2022) A review in radiomics: making personalized medicine a reality via routine imaging. Med Res Rev 42(1):426–440

71. Si L, Zhong J, Huo J et al (2022) Deep learning in knee imaging: a systematic review utilizing a Checklist for Artificial Intelligence in Medical Imaging (CLAIM). Eur Radiol 32(2):1353–1361

72. Ursprung S, Beer L, Bruining A et al (2020) Radiomics of computed tomography and magnetic resonance imaging in renal cell carcinoma—a systematic review and meta-analysis. Eur Radiol 30(6):3558–3566

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.